(A) miR-17-92 pathway activity is scored in three clinicogenetic subsets of neuroblastoma tumors (dataset D1, Supplemental Table 1), MYCN amplified tumors (MNA), MYCN single copy high-risk tumors (SH) and MYCN single copy low risk tumors (SL) (whiskers: Tukey). miR-17-92 pathway activity score is significantly higher in MNA vs. SH (Mann Whitney, p < 0.05), MNA vs. SL (p < 0.0001) and SH vs. SL (p < 0.01). (B) Kaplan Meier plots for overall (OS) and event free survival (EFS) based on the pathway activity score of miR-17-92, represented as quartiles. Increased activity of miR-17-92 is proportionally correlated to both poor overall and event-free survival.